Anzeige
Erschienen in:
01.06.2011 | Article
Serum cystatin C and the incidence of type 2 diabetes mellitus
Erschienen in: Diabetologia | Ausgabe 6/2011
Einloggen, um Zugang zu erhaltenAbstract
Aims/hypothesis
To examine the association of serum cystatin C with the incidence of type 2 diabetes mellitus over a 15 year follow-up period.
Methods
The 15 year cumulative incidence of diabetes was measured in a cohort of Beaver Dam Eye Study participants (n = 3,472, 1988–2003). A person was defined as developing diabetes (a positive history of diabetes mellitus treated with insulin, oral hypoglycaemic agents and/or diet, or elevations in glycosylated haemoglobin levels) in the absence of diabetes at baseline. The relation of cystatin C and other risk factors to incident type 2 diabetes was determined using discrete time extension of the proportional hazards model.
Results
The 15 year cumulative incidence of diabetes was estimated to be 9.6%. After controlling for age, sex, body mass index, smoking status, glycosylated haemoglobin, proteinuria, chronic kidney disease status and hypertension status, serum cystatin C at baseline was associated with the 15 year cumulative incidence of type 2 diabetes (OR per log of cystatin C unit 2.19, 95% CI 1.02–4.68).
Conclusions/interpretation
These findings show a positive relationship of serum cystatin C levels with the incidence of type 2 diabetes mellitus independently of confounding risk factors. The findings strongly suggest the need for further evaluation of the potential importance of cystatin C in the pathogenesis of type 2 diabetes mellitus.